Intravesical interleukin-2 in T1 papillary bladder carcinoma: Regression of marker lesion in 8 of 10 patients

Journal of Urology

Volumn 159, Issue 4, 1998, Pages 1183-1186

  Den Otter, Willem ^a   Dobrowolski, Zygmunt ^a   Bugajski, Andrej ^a   Papla, Bolesław ^a   Van Der Meijden, A P M ^a   Koten, Jan W ^a   Boon, Tom A ^a   Siedlar, Maciej ^a   Zembala, Marek ^a  

^a NONE

Author keywords

Bladder; Carcinoma; Immunotherapy; Interleukin 2

Indexed keywords

BCG VACCINE; INTERLEUKIN 2;

ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER CARCINOMA; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MALE; PAPILLARY CARCINOMA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031897859     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63548-1     Document Type: Article

References (20)

1. Den Otter, W., Hill, F. W., Klein, W. R., Koten, J. W., Steerenberg, P. A., De Mulder, P. H., Rutten, V. P. and Ruitenberg, E. J.: Low doses of interleukin-2 can cure large bovine ocular squamous cell carcinoma. Anticancer Res., 13: 2453, 1993.
2. Den Otter, W., Hill, F. W., Klein, W. R., Koten, J. W., Steerenberg, P. A., De Mulder, P. H., Rhode, C., Stewart, R., Faber, J. A., Ruitenberg, E. J. and Rutten, V. P. M.: Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up. Cancer Immunol. Immunother., 41: 10, 1995.
3. Den Otter, W., De Groot, J. W., Bernsen, M. R., Heintz, A. P., Maas, R., Hordijk, G. J., Hill, F. W., Klein, W. R., Ruitenberg, E. J. and Rutten, V. P. M.: Optimal regimes for local IL-2 tumour therapy. Int. J. Cancer, 66: 400, 1996.
4. Hill, F. W., Klein, W. R., Hoyer, M. J., Rutten, V. P., Kock, N., Koten, J. W., Steerenberg, P. A., Ruitenberg, E. J. and Den Otter, W.: Antitumor effect of locally injected low doses of recombinant human interleukin-2 in bovine vulval papilloma and carcinoma. Vet. Immunol. Immunopathol., 41: 19, 1994.
5. Van der Meijden, A. P., Steerenberg, P. A., de Jong, W. H. and Debruyne, F. M.: Intravesical bacillus Calmette-Guérin treatment for superficial bladder cancer: results after 15 years of experience. Anticancer Res., 11: 1253, 1991.
6. Lage, J. M., Bauer, W. C., Kelley, D. R., Ratliff, T. L. and Catalona, W. J.: Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guerin treatment of superficial bladder cancer. J. Urol., 135: 916, 1986.
7. Standard Phase II Protocol for Patients With Intermediate Risk Ta/T1 Papillary Carcinoma of the Urinary Bladder. European Organisation for Research and Treatment of Cancer-Genito-Urinary Group protocol 30940, 1994.
8. Van der Meijden, A. P. M., Kurth, K. H., Cheuvart, B., Sylvester, R. and Debruyne, F. M. J.: Intravesical chemotherapy for superficial bladder cancer. The EORTC Genito-Urinary Group experience. In: Recent Advances in Urologic Cancers: Diagnosis and Treatment. Edited by G. Murphy, S. Khoury, C. Chatelain and L. Denis, pp. 138-143. 1990.
9. Van der Meijden, A. P., Hall, R. R., Kurth, K. H., Bouffioux, C. and Sylvester, R.: Phase II trials in Ta, T1 bladder cancer. The marker tumour concept. Brit. J. Urol., 77: 634, 1996.
10. Lamm, D. L., Van der Meijden, A. P., Akaza, H., Brendler, C., Hedlund, P. O., Mizutani, Y., Ratliff, T. L., Robinson, M. R. and Shinka, T.: Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses? Int. J. Urol., suppl. 2, 2: 23, 1995.
11. Pizza, G., Severini, G., Menniti, D., De Vinci, C. and Corrado, F.: Tumor regression after intralesional injection of interleukin-2 (IL-2) in bladder cancer. Preliminary report. Int. J. Cancer, 34: 359, 1984.
12. Pizza, G., Berton, F., Casanova, S., De Vinci, C. and Corrado, F.: Interleukin-2 in the treatment of infiltrating bladder cancer. J. Exp. Path., 3: 525, 1987.
13. Huland, E. and Huland, H.: Local continuous high dose interleukin-2: a new therapeutic model for the treatment of advanced bladder cancer. Cancer Res., 49: 5469, 1989.
14. Ferlazzo, G., Magno, C., Lupo, G., Rizzo, M., Iemmo, R., Semino, C. and Melioli, G.: A phase I study of intravesical continuous perfusion of recombinant interleukin-2 in patients with superficial bladder cancer. Amer. J. Clin. Oncol., 18: 100, 1995.
15. Lissoni, P., Barni, S., Ardizzoia, A., Paolorossi, F., Tisi, E., Crispino, S. and Tancini, G.: Intracavitary administration of interleukin-2 as palliative therapy for neoplastic effusions. Tumori, 78: 118, 1992.
16. Tubaro, A., Stoppacciaro, A., Velotti, F., Bossola, P. C., Cusumano, G., Vicenti, C., De Carli, P., Ruco, L., Santoni, A. and Cancrini, A.: Local immunotherapy of superficial bladder cancer by intravesical instillation of recombinant interleukin-2. Eur. Urol., 28: 297, 1995.
17. Fellows, G. J., Parmar, M. K., Grigor, K. M., Hall, R. R., Heal, M. R. and Wallace, D. M.: Marker tumour response to Evans and Pasteur bacille Calmette-Guerin in multiple recurrent pTa, pT1 bladder tumours: report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Brit J. Urol., 73: 639, 1994.
18. Oosterlinck, W., Kurth, K. H., Schröder, F., Bultinck, J., Hammond, B., Sylvester, R. and members of the European Organization for Research and Treatment of Cancer Genito-urinary Group: A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J. Urol., 149: 749, 1993.
19. Popert, R. J. M., Goodall, J., Coptcoat, M. J., Thompson, P. M., Parmar, M. K., and Masters, J. R.: Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin. Brit. J. Urol., 74: 195, 1994.
20. Van der Meijden, A. P., Hall, R. R., Macaluso, M. P., Pawinsky, A., Sylvester, R. and Van Glabbeke, M.: Marker tumour response to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group. Eur. Urol., 29: 199, 1996.